Serotonin 5-HT1B receptor antagonist
 ;templatestyles src="Infobox drug/styles.css"/ ;
}}|[[Category:Infobox drug articles with contradicting parameter input| ]]}}{{#if:|{{#if:
 [[Serotonin]] [[5-HT1B receptor|5-HT1B receptor]] [[receptor antagonist|antagonist]]
}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to watched fields]]
NAS-181, also known as MCOMM, is a [[binding selectivity|selective]] rodent [[serotonin]] [[5-HT1B receptor|5-HT1B receptor]] [[receptor antagonist|antagonist]] which is used in [[scientific research]].
In animals, NAS-181 has been found to strongly increase [[acetylcholine]] levels in the [[frontal cortex]] and [[hippocampus]]. It has been found to block [[memory impairment]] induced by the [[antimuscarinic agent]] [[scopolamine]] and by the [[NMDA receptor antagonist]] [[dizocilpine]] (MK-801). Injection of NAS-181 directly into the [[nucleus accumbens]] has also been found to reverse the [[prosocial]] behavior induced by the [[serotonin releasing agent]] [[MDMA]] in animals.
NAS-181 was first described in the [[scientific literature]] by 1998. The drug was discovered by researchers at Astra Arcus.
References.
 ;templatestyles src="Reflist/styles.css" / ;
[[Category:5-HT1B antagonists]]
[[Category:Benzopyrans]]
[[Category:Experimental drugs]]
[[Category:Morpholines]]